TP53 and myelodysplastic syndrome: In an analysis of the French and Spanish compassionate treatment programs involving a total of 107 patients, cytogenetic response to lenalidomide in del(5q) MDS ranged from 0 to 12% in patients with mutated TP53 compared to 73% in patients with wild-type (WT) TP53 (41–43).